Seikagaku Corp. | Balance Sheet

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Cash & Short Term Investments
12,575
12,511
13,266
11,749
11,509
16,739
Total Accounts Receivable
7,776
8,356
8,014
7,954
8,693
8,287
Inventories
5,667
6,224
7,259
6,805
7,576
7,554
Other Current Assets
2,640
2,753
2,730
1,673
3,162
1,807
Total Current Assets
28,658
29,844
31,269
28,186
30,942
34,390
Net Property, Plant & Equipment
26,918
25,928
24,668
22,716
21,275
19,656
Total Investments and Advances
17,737
24,099
23,678
25,787
28,959
24,114
Intangible Assets
228
347
331
479
554
577
Other Assets
285
671
272
2,878
3,018
1,499
Total Assets
74,251
81,233
80,752
80,372
84,834
80,859
ST Debt & Current Portion LT Debt
256
461
465
470
348
Accounts Payable
1,320
1,349
1,809
1,846
1,780
Income Tax Payable
940
89
379
110
545
Other Current Liabilities
4,149
4,462
4,038
3,768
5,002
Total Current Liabilities
6,665
6,361
6,691
6,194
7,675
Long-Term Debt
1,047
1,854
1,412
973
684
Provision for Risks & Charges
293
36
892
387
38
Deferred Taxes
918
2,091
1,269
1,709
2,269
Other Liabilities
118
137
139
135
133
Total Liabilities
9,466
10,823
10,937
9,722
10,885
Common Equity (Total)
64,785
70,410
69,815
70,646
73,945
Total Shareholders' Equity
64,785
70,410
69,815
70,646
73,945
Total Equity
64,785
70,410
69,815
70,646
73,945
Liabilities & Shareholders' Equity
74,251
81,233
80,752
80,368
84,830

About Seikagaku

View Profile
Address
Marunouchi Center Building, 10/F
Tokyo Tokyo 100
Japan
Employees -
Website http://www.seikagaku.co.jp
Updated 07/08/2019
Seikagaku Corp. engages in the manufacture and sale of pharmaceuticals and medical devices specifically related to glycoconjugates. It operates through the following segments: Pharmaceuticals and Limulus Amebocyte Lysate (LAL). The Pharmaceuticals segment develops and supplies intra-articular injections for improving joint functions, cross-linked hyaluronate hydrogel for knee osteoarthritis, opthalmic surgical aids, and surgical aids for endoscopic mucosal resection.